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Dear Editor,
The HLA-A, HLA-B, and HLA-DR loci have been used for trans-
plant candidate matching. Recent studies using single antigen 
bead-based assays (SABAs) have revealed that HLA-DQ donor-
specific HLA antibodies (DSHAs) are associated with inferior al-
lograft outcomes [1, 2]. Therefore, donor HLA-DQ typing prior 
to transplantation is now thought to be highly important. 
HLA-DQ antigen typing is determined by HLA-DQB1 genotyp-
ing. The HLA-DQ antigen is composed of two alpha protein do-
mains, coded by the DQA1 gene, and two beta protein domains, 
coded by the DQB1 gene. HLA-DQ antigen Luminex SABA beads 
are coated with both DQ alpha and DQ beta proteins. Therefore, 
DQ alpha proteins are taken into account in the interpretation of 
HLA-DQ antibody reactions. However, the clinical significance of 
DQ alpha-specific DSHA is questionable. In addition, although 
the clinical significance of allele-specific DSHAs has been es-
tablished, the routine application of high-resolution HLA geno-
typing remains controversial [3-5]. 
We report two representative cases of antibody-mediated re-
jection (ABMR) following kidney transplantation (KT) due to HLA-
DQB1 allele-specific DSHA and DQ alpha protein-specific DSHA.
HLA typing assays for detecting the HLA-A, -B, -DRB1, and 
-DQB1 loci were performed by using Luminex technology and 
LIFECODES HLA SSO typing kits (Immucor Transplant Technol-
ogy, Stamford, CT, USA). High-resolution HLA-DQB1 and DQA1 
typing results were achieved through direct sequencing of exons 
2, 3 of the HLA-DQB1 gene and exons 1, 2, 3, 4 of the HLA-
DQA1 gene, using the ABI PRISM 3100 Genetic analyser (Ap-
plied Biosystems, Hitachi, Japan). SABAs were performed by 
using two commercially available Luminex assays (LIFECODES 
Single Antigen Class I/II [Immucor Transplant Technology] and 
LABScreen Single Antigen Class I and II [One Lambda, Canoga 
Park, CA, USA]) and the C1q assay (C1q Screen; One Lambda) 
was performed to determine DSHA status. 
CASE 1
A 21-yr-old woman with end-stage renal disease caused by lu-
pus nephritis received a KT from her mother with 0% calculated 
panel reactive antibody (PRA) in February 2010. Four years fol-
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lowing the KT, serum creatinine levels increased to 2.32 mg/dL 
and a biopsy of the allograft kidney revealed active ABMR with 
diffusely positive deposition of C4d, g3 (glomerulitis, score 3), 
and ptc3 (peritubular capillaritis, score 3). At the time of rejec-
tion, only HLA-DQ6 class II HLA antibodies were identified by 
SABA. No HLA-DQ mismatch was revealed by antigen-level typ-
ing. Therefore, high-resolution HLA-DQB1 and DQA1 typing were 
performed and an HLA-DQB1*06:01 allele-specific DSHA was 
identified. The C1q assay revealed positive C1q fixing for HLA-
DQB1*06:01 DSHA (Table 1).
Table 1. HLA typing and antibody reaction results for case 1 (HLA-DQB1 allele-specific DSHA)
HLA typing A B C DRB1 DQB1 DQA1
Recipient 11, 26 44, 62 05, 09 04, 13 04:01 (DQ4), 06:03 (DQ6) 01:03, 03:03
Donor (mother) 11, 26 39, 44 05, 07 08, 13 06:01 (DQ6), 06:03 (DQ6) 01:03, 01:03
Antibody reactions by SABA  
   HLA-DQB1 and -DQA1 specificity of HLA-DQ beads Raw MFI from Immucor Baseline MFI from One 
Lambda
Baseline MFI for C1q assay
DQB1*06:01 (DQ6)-DQA1*01:03 11,941 7,111 14,633
DQB1*06:01 (DQ6)-DQA1*02:01 11,827 NA NA
DQB1*06:01 (DQ6)- DQA1*01:04 10,761 NA NA
DQB1*06:09 (DQ6)- DQA1*01:02 NA 6,155 0
DQB1*06:02 (DQ6)- DQA1*01:01 NA 314 0
DQB1*06:03 (DQ6)- DQA1*01:03 NA 0 0
DQB1*06:04 (DQ6)- DQA1*01:02   3,233 591 0
Abbreviations: DSHA, donor-specific HLA antibody; SABA, single antigen bead assay; MFI, mean fluorescence intensity; NA, not applicable.
Table 2. HLA typing and antibody reaction results for case 2 (HLA-DQA1-specific DSHA)
HLA typing A B DRB1 DQB1 DQA1
Recipient 02, 33 48, 61 12, 14 03:01 (DQ7), 05:03 (DQ5) 01:04, 05:08
Donor (mother) 02, 26 48, 55 12, 14 03:01 (DQ7), 05:03 (DQ5) 01:04, 06:01
Antibody reactions by SABA
   HLA-DQB1 and -DQA1 specificity of HLA-DQ beads Raw MFI from Immucor Baseline MFI from One Lambda
DQB1*02:01 (DQ2)-DQA1*04:01 NA 3,867
DQB1*03:03 (DQ9)-DQA1*04:01 3,004 NA
DQB1*04:02 (DQ4)-DQA1*04:01 2,833 5,219
DQB1*04:01 (DQ4)-DQA1*04:01 2,599 NA
DQB1*02:01 (DQ2)-DQA1*05:01 1,323 4,626
DQB1*02:02 (DQ2)-DQA1*05:01 1,450 NA
DQB1*04:01 (DQ4)-DQA1*05:01 2,003 NA
DQB1*03:01 (DQ7)-DQA1*02:01 NA Negative
DQB1*03:01 (DQ7)-DQA1*03:01 NA Negative
DQB1*03:01 (DQ7)-DQA1*03:02 Negative NA
DQB1*03:01 (DQ7)-DQA1*05:01 2,993 NA
DQB1*03:01 (DQ7)-DQA1*05:03 NA 4,627
DQB1*03:01 (DQ7)-DQA1*05:05 NA 3,174
DQB1*03:01 (DQ7)-DQA1*06:01 2,538 4,591
DQB1*03:03 (DQ9)-DQA1*06:01 2,386 NA
DQB1*04:02 (DQ4)-DQA1*06:01 2,075 NA
Abbreviations: see Table 1. 
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CASE 2
A 23-yr-old woman with end-stage renal disease caused by IgA 
nephropathy received a KT with 0% calculated PRA from her 
mother in August 2011. Three years later, her creatinine level in-
creased to 2.24 mg/dL, and a biopsy of the allograft kidney re-
vealed active T-cell-mediated rejection (TCMR). Four months 
later, the creatinine level increased to 6.17 mg/dL, and the al-
lograft biopsy revealed TCMR with active ABMR, grade II with 
C4d negative, g1, and ptc3. Several class II HLA antibodies were 
identified by SABA. Both donor and recipient’s HLA-DQ antigens 
were identified as HLA-DQ5 and DQ7. However, the HLA-DQ7 
antibody reactions in serum were positive against two of the three 
Immucor DQ7 beads and three of five One Lambda beads. High-
resolution HLA-DQB1 and DQA1 typing revealed donor HLA-
DQA1*06:01 that was different from patient HLA-DQA1 gene.
The HLA antibody reactions were positive for HLA-DQA1*04:01, 
DQA1*05:01, DQA1*05:03, DQA1*05:05, and DQA1*06:01; 
these alleles share a confirmed epitope, 40GR3 (40G 41R 45V 
47C 48L 50V 51L 52R 53Q 54F 55R, according to the HLA epi-
tope registry). Therefore, the recipient antibody reaction was iden-
tified as HLA-DQA1*06:01-specific DSHA (Table 2).
HLA antibodies against DQ alpha antigens are observed in up 
to 79% of highly sensitized patients [5]. HLA-DQ antibodies show 
activity against both DQ alpha and beta proteins; however, their 
specific reactions against each type of protein cannot be easily 
differentiated. Our second case did not exhibit HLA antibodies 
prior to KT; however, HLA-DQ alpha protein-specific DSHA de-
veloped four years after transplantation, and the allograft biopsy 
revealed C4d negative ABMR. 
Allele-specific DSHAs have been reported to have clinical sig-
nificances [4]. However, only one of 67 crossmatches was posi-
tive for allele-specific DSHAs [6]. Therefore, the clinical signifi-
cance of these DSHAs requires further investigation. 
Our two cases showed biopsy-proven ABMR due to HLA-DQB1 
allele-specific DSHA and DQ alpha protein-specific DSHA. Al-
though HLA-DQ typing is not included in routine HLA antigen-
matching strategies, it must be performed to evaluate DSHA fol-
lowing KT. In addition, high-resolution HLA-DQB1 and DQA1 
typing results should be considered when necessary for the in-
terpretation of DSHAs in SABA.
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